FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1784013709> ?p ?o ?g. }

• W1784013709 abstract "The IFCT-GFPC 0502 phase III study reported prolongation of progression-free survival with gemcitabine or erlotinib maintenance vs. observation after cisplatin-gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). This analysis was undertaken to assess the incremental cost-effectiveness ratio (ICER) of these strategies for the global population and pre-specified subgroups.A cost-utility analysis evaluated the ICER of gemcitabine or erlotinib maintenance therapy vs. observation, from randomization until the end of follow-up. Direct medical costs (including drugs, hospitalization, follow-up examinations, second-line treatments and palliative care) were prospectively collected per patient during the trial, until death, from the primary health-insurance provider's perspective. Utility data were extracted from literature. Sensitivity analyses were conducted.The ICERs for gemcitabine or erlotinib maintenance therapy were respectively 76,625 and 184,733 euros per quality-adjusted life year (QALY). Gemcitabine continuation maintenance therapy had a favourable ICER in patients with PS = 0 (52,213 €/QALY), in responders to induction chemotherapy (64,296 €/QALY), regardless of histology (adenocarcinoma, 62,292 €/QALY, non adenocarcinoma, 83,291 €/QALY). Erlotinib maintenance showed a favourable ICER in patients with PS = 0 (94,908 €/QALY), in patients with adenocarcinoma (97,160 €/QALY) and in patient with objective response to induction (101,186 €/QALY), but it is not cost-effective in patients with PS =1, in patients with non-adenocarcinoma or with stable disease after induction chemotherapy.Gemcitabine- or erlotinib-maintenance therapy had ICERs that varied as a function of histology, PS and response to first-line chemotherapy." @default.
• W1784013709 created "2016-06-24" @default.
• W1784013709 creator A5016370905 @default.
• W1784013709 creator A5019588141 @default.
• W1784013709 creator A5022875313 @default.
• W1784013709 creator A5027488058 @default.
• W1784013709 creator A5039103158 @default.
• W1784013709 creator A5040900859 @default.
• W1784013709 creator A5043045128 @default.
• W1784013709 creator A5044439829 @default.
• W1784013709 creator A5047402540 @default.
• W1784013709 creator A5048784388 @default.
• W1784013709 creator A5053842558 @default.
• W1784013709 creator A5054233620 @default.
• W1784013709 creator A5055716383 @default.
• W1784013709 creator A5059770969 @default.
• W1784013709 creator A5063103135 @default.
• W1784013709 creator A5063465326 @default.
• W1784013709 creator A5064215820 @default.
• W1784013709 creator A5065667511 @default.
• W1784013709 creator A5072758102 @default.
• W1784013709 date "2014-12-01" @default.
• W1784013709 modified "2023-10-08" @default.
• W1784013709 title "Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study" @default.
• W1784013709 cites W1973644773 @default.
• W1784013709 cites W1990569211 @default.
• W1784013709 cites W1995797888 @default.
• W1784013709 cites W2005244154 @default.
• W1784013709 cites W2009877955 @default.
• W1784013709 cites W2011321004 @default.
• W1784013709 cites W2068267496 @default.
• W1784013709 cites W2079904602 @default.
• W1784013709 cites W2096216990 @default.
• W1784013709 cites W2100912832 @default.
• W1784013709 cites W2104874286 @default.
• W1784013709 cites W2112621029 @default.
• W1784013709 cites W2119391913 @default.
• W1784013709 cites W2128473443 @default.
• W1784013709 cites W2131988196 @default.
• W1784013709 cites W2136023414 @default.
• W1784013709 cites W2144660856 @default.
• W1784013709 cites W2145835533 @default.
• W1784013709 cites W2150230663 @default.
• W1784013709 cites W2154826375 @default.
• W1784013709 cites W2156438240 @default.
• W1784013709 cites W2166164739 @default.
• W1784013709 cites W2166791204 @default.
• W1784013709 cites W2168340462 @default.
• W1784013709 cites W2170915815 @default.
• W1784013709 doi "https://doi.org/10.1186/1471-2407-14-953" @default.
• W1784013709 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4302067" @default.
• W1784013709 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25511923" @default.
• W1784013709 hasPublicationYear "2014" @default.
• W1784013709 type Work @default.
• W1784013709 sameAs 1784013709 @default.
• W1784013709 citedByCount "9" @default.
• W1784013709 countsByYear W17840137092015 @default.
• W1784013709 countsByYear W17840137092016 @default.
• W1784013709 countsByYear W17840137092017 @default.
• W1784013709 countsByYear W17840137092018 @default.
• W1784013709 countsByYear W17840137092019 @default.
• W1784013709 countsByYear W17840137092022 @default.
• W1784013709 crossrefType "journal-article" @default.
• W1784013709 hasAuthorship W1784013709A5016370905 @default.
• W1784013709 hasAuthorship W1784013709A5019588141 @default.
• W1784013709 hasAuthorship W1784013709A5022875313 @default.
• W1784013709 hasAuthorship W1784013709A5027488058 @default.
• W1784013709 hasAuthorship W1784013709A5039103158 @default.
• W1784013709 hasAuthorship W1784013709A5040900859 @default.
• W1784013709 hasAuthorship W1784013709A5043045128 @default.
• W1784013709 hasAuthorship W1784013709A5044439829 @default.
• W1784013709 hasAuthorship W1784013709A5047402540 @default.
• W1784013709 hasAuthorship W1784013709A5048784388 @default.
• W1784013709 hasAuthorship W1784013709A5053842558 @default.
• W1784013709 hasAuthorship W1784013709A5054233620 @default.
• W1784013709 hasAuthorship W1784013709A5055716383 @default.
• W1784013709 hasAuthorship W1784013709A5059770969 @default.
• W1784013709 hasAuthorship W1784013709A5063103135 @default.
• W1784013709 hasAuthorship W1784013709A5063465326 @default.
• W1784013709 hasAuthorship W1784013709A5064215820 @default.
• W1784013709 hasAuthorship W1784013709A5065667511 @default.
• W1784013709 hasAuthorship W1784013709A5072758102 @default.
• W1784013709 hasBestOaLocation W17840137091 @default.
• W1784013709 hasConcept C121608353 @default.
• W1784013709 hasConcept C126322002 @default.
• W1784013709 hasConcept C141071460 @default.
• W1784013709 hasConcept C143998085 @default.
• W1784013709 hasConcept C2776611710 @default.
• W1784013709 hasConcept C2776694085 @default.
• W1784013709 hasConcept C2778087573 @default.
• W1784013709 hasConcept C2779438470 @default.
• W1784013709 hasConcept C2780258809 @default.
• W1784013709 hasConcept C2908647359 @default.
• W1784013709 hasConcept C71924100 @default.
• W1784013709 hasConcept C99454951 @default.
• W1784013709 hasConceptScore W1784013709C121608353 @default.
• W1784013709 hasConceptScore W1784013709C126322002 @default.
• W1784013709 hasConceptScore W1784013709C141071460 @default.
• W1784013709 hasConceptScore W1784013709C143998085 @default.
• W1784013709 hasConceptScore W1784013709C2776611710 @default.

• next